Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (781)	12/22/2003 10:44:06 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

PRINCETON, N.J., Dec. 22 /PRNewswire/ -- Medarex and its licensees have advanced 16 fully human antibodies derived from Medarex's UltiMAb Human Antibody Development System(R) either into human clinical trials or regulatory applications have been submitted to begin such trials. Genmab A/S recently announced the filing of an Investigational New Drug application and a Clinical Trial Application in England for HuMax-CD20 for the treatment of non-Hodgkin's lymphoma. HuMax-CD20 is the sixteenth UltiMAb-derived antibody to begin the clinical development process. Five antibody therapeutics are under development by Medarex for a variety of diseases, including melanoma, prostate cancer, breast cancer, HIV, Hodgkin's lymphoma and anaplastic large cell lymphoma as well as autoimmune diseases. Medarex licensees, including Genmab A/S, Centocor/J&J, and Novartis among others, are developing fully human antibodies for diseases such as cancer, lymphoma, rheumatoid arthritis, psoriasis and other autoimmune diseases.